These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1132 related articles for article (PubMed ID: 18448208)

  • 1. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
    Wu R; Chen Q; Zheng L; Chen J; Sui Z; Guan Y; Chen Z
    Arch Virol; 2009; 154(8):1203-10. PubMed ID: 19543688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea.
    Song JM; Lee YJ; Jeong OM; Kang HM; Kim HR; Kwon JH; Kim JH; Seong BL; Kim YJ
    Vet Microbiol; 2008 Aug; 130(3-4):268-76. PubMed ID: 18374520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and antigenic relatedness of H3 subtype influenza A viruses isolated from avian and mammalian species.
    Yassine HM; Lee CW; Suarez DL; Saif YM
    Vaccine; 2008 Feb; 26(7):966-77. PubMed ID: 18206275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
    Chen H; Subbarao K; Swayne D; Chen Q; Lu X; Katz J; Cox N; Matsuoka Y
    Vaccine; 2003 May; 21(17-18):1974-9. PubMed ID: 12706686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
    Wen F; Yu H; Yang FR; Huang M; Yang S; Zhou YJ; Li ZJ; Tong GZ
    Arch Virol; 2014 Nov; 159(11):2957-67. PubMed ID: 24957653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
    Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
    Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.
    Lee CW; Senne DA; Suarez DL
    Vaccine; 2004 Aug; 22(23-24):3175-81. PubMed ID: 15297071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
    Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
    Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
    Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
    Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of vaccine strains of H5 and H7 influenza viruses.
    Soda K; Sakoda Y; Isoda N; Kajihara M; Haraguchi Y; Shibuya H; Yoshida H; Sasaki T; Sakamoto R; Saijo K; Hagiwara J; Kida H
    Jpn J Vet Res; 2008 Jan; 55(2-3):93-8. PubMed ID: 18318111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.